Phibro Animal Health | PAHC - Cash And Equivalent


Phibro Animal Health reported $54.93M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Align Technology USD 1.06B 35.07M Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Assertio Holdings USD 38.5M 8.59M Sep/2025
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Canopy Growth CAD 371.32M 73.26M Dec/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Henry Schein USD 138M 18M Mar/2026
Idexx Laboratories USD 200.53M 20.46M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Pacira USD 144.31M 14.24M Mar/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 63.87M 1.5M Mar/2026
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Zoetis USD 1.94B 369M Mar/2026